Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
  • G01N33/6848—Methods of protein analysis involving mass spectrometry
  • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
  • G01N33/6848—Methods of protein analysis involving mass spectrometry
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
  • G01N33/721—Haemoglobin
  • G01N33/723—Glycosylated haemoglobin
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/04—Endocrine or metabolic disorders
  • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Definitions

• the present invention relates to a method for measuring the levels of non-glycated and glycated hemoglobin within a blood sample using direct mass spectral analysis.
• the proportion of hemoglobin molecules which are glycated can be used to diagnose pre-diabetes or diabetes.
• Diabetes and in particular type 2 diabetes is now a public health issue in the developed and developing worlds.
• Costly diabetic complications include cardiovascular disease, retinopathy, neuropathy, and nephropathy.
• a significant unmet medical needs exist in both detecting and evaluating patients and screening aging populations of a nation for early onset diabetes. For example, in 2011 it was estimated that 25.8 million children and adults in the U.S. (8.3% of the population), have diabetes. While an estimated 18.8 million have been diagnosed with Type 2 diabetes, approximately 7 million are unaware they have the disease. Based on glycaemic measures from 2005-2008, the Centers for Disease Control and Prevention (CDC), reported that 35% of the U.S.
• CDC Centers for Disease Control and Prevention
• Detection of diabetes has been traditionally via measurement of glucose levels in blood and urine.
• a glucose tolerance test is taken whereby, following an oral glucose challenge, blood glucose levels are measured, over a timed period, to monitor the maxima and magnitude before levels are brought back to normal.
• insulin levels can be measured in parallel however the glucose tolerance test requires admittance as a day patient.
• Glycated Hemoglobin is formed in a non-enzymatic glycation pathway by which hemoglobin's (Hb) reacts freely with blood plasma glucose, even though it is contained within red blood cells.
• Hb hemoglobin's
• measurement of glycated Hb therefore reflects the cumulative exposure to glucose: Normal levels of glucose produce a normal amount of glycated hemoglobin; as the average amount of plasma glucose increases, the fraction of glycated hemoglobin increases. Thus, it is a marker for average blood glucose levels over the months prior to the measurement. Rather than a one off test this provides solid evidence of increasing metabolic problems such as pre diabetes. Indeed measurement of glycated Hb provides a much more reliable measure of how well a patient is controlling their diabetes than food and blood glucose diaries.
• HbAi C a recently favoured test of glycated Hb is the measurement of HbAi C levels, relative to HbA levels.
• HbAi C is so named because Hb is usually analysed and measured by elution from reverse phase high pressure liquid chromatography. The chromatographic separation of total Hb resolves the different types of hemoglobin, principally A and A2, from fetal Hb and disease variant of these two types. A minor resolved elution peak is glycated Hb called HbA lc .
• the measurement of HbA lc is the preferred test for diabetes and the onset of metabolic disease as glycated Hb is a cumulative and non-patient compliance dependant test.
• HbA lc Point of care testing for HbA lc is recommended by the American Diabetes Association, as it is rapid and allows the clinician to address the patient's status immediately, improving patient compliance.
• Hemoglobin A 1C was recently approved for use as a diagnostic tool, and an HbA lc of greater than or equal to 6.5% is the cut-off point for diagnosis.
• the pre-diabetic state was cited to be an HbA lc > 5.7 to 6.4%.
• the correlation of HbA lc to average glucose concentration was recently validated with patients who have type 2 diabetes mellitus.
• HbA lc is not suitable for patients with variant Hb or hemoglobinopathies such as sickle cell trait. This can be because the elution profile of the glycated Hb can be obscured by the elution profile of the variant Hb or it interferes with the differential specificity of HbAi C immunoassays.
• a second problem is that, as reported in the WHO 2011 report WHO/NMH/CHP/CPM/11.1, Use of Glycated Hemoglobin (HbA lc ) in the Diagnosis of Diabetes Mellitus, current HbA lc assays are "unaffordable in most low and middle-income country settings".
• the invention describes a rapid robust and affordable method for screening population for diabetes and pre diabetic metabolic syndromes by analysing blood samples.
• the invention describes direct mass spectrographic analysis of a blood sample, which can be lysed and optionally diluted 100-1000 fold in water.
• the Hb species present in the sample can be resolved by direct mass spectral analysis such as matrix assisted laser desorption time of flight mass spectrometry.
• the Hb a-globin chain resolved from the glycated species - Hb a-globin Glc, and/or Hb ⁇ -globin from Hb ⁇ -globin Glc can be measured for example by normalized area under the curve or peak height.
• Hb and hemoglobinopathies are resolved and are not influential on the measurement of percentage glycated Hb, as the Hb a-chain and/or Hb ⁇ -chain and respective glycated (Glc) orthologos can be used as the differential marker of diabetic glycosylation.
• the invention describes a method to help manage and reduce a cause of socio-economic burden on a nation, through early detection and monitoring.
• the method describes rapid screening of whole blood samples, such as pin prick samples and blood spot cards, subjected to direct mass spectral analysis, such as MALDI - ToF Mass spectrometry. Analysis may be carried out following lysis, for example in distilled deionised water, or by freezing, and optionally massive dilution at the range of 1/10 to 1/8000 (preferably 1/2000) in for example distilled deionised H 2 0 or 0.1% trifluoroacetic acid (TFA) in distilled deionised H 2 0.
• lysis for example in distilled deionised water, or by freezing, and optionally massive dilution at the range of 1/10 to 1/8000 (preferably 1/2000) in for example distilled deionised H 2 0 or 0.1% trifluoroacetic acid (TFA) in distilled deionised H 2 0.
• TFA trifluoroacetic acid
• the resulting spectra is examined as singly charged ions at the Mass/charge range of 15,000 m/z to 16,200 m/z; and/or the doubly charged ions at 7,550 to 8,100 m/z or 7,550 to 8,200 m/z.
• Unglycated a- globin is preferably measured at 7,564 m/z
• Glycated a globin is preferably measured at 7,645 m/z
• Unglycated ⁇ -globin is preferably measured at 7,934 m/z
• Glycated ⁇ -globin is preferably measured at 8,017 m/z
• the spectra is generated using a matrix, preferably sinapinic acid, and intensity of the characteristic resolved mass peaks of a-globin and glycated a-globin, and/or ⁇ -globin and glycated ⁇ -globin are measured and a ratio determines the relative percentage glycated globin.
• the determined relative percentage is indicative of pre-diabetes, diabetes and diabetic patients control of cumulative average blood glucose over the previous 2-3 months.
• the invention provides a method of detecting pre-diabetes or diabetes comprising subjecting a blood sample obtained from a subject to direct mass spectral analysis and determining the proportion of glycated hemoglobin (Hb) e.g. glycated ⁇ -globin and/or glycated ⁇ -globin present in the sample.
• Hb glycated hemoglobin
• Direct mass spectral analysis means that the data generated from the mass spectral analysis is used in the method, and not the inferred mass of the components present in the sample.
• Pre-diabetes also referred to as borderline diabetes is usually a precursor to diabetes. It occurs when the blood glucose levels are higher than normal, but not high enough for the patient to be considered to have diabetes. It is often described as the "grey area" between normal blood sugar and diabetic levels.
• Pre-diabetes may be also be referred to as impaired fasting glucose (IFT), if a patient has higher than normal sugar levels after a period of fasting, or as impaired glucose tolerance (IGT), if a patient has higher than normal sugar levels following eating.
• IFT impaired fasting glucose
• ITT impaired glucose tolerance
• the blood sample can be an untreated sample.
• the blood sample may be diluted or processed (concentrated, filtered, etc.).
• the blood sample can be a whole blood sample collected using conventional phlebotomy methods.
• the sample can be obtained through venupuncture or as a pin prick sample, such as a finger-stick or heel prick.
• the blood sample may be a dried blood spot captured on filter paper or other suitable blood spot capture material.
• the blood sample is preferably treated to lyse the red blood cells. This can be done by diluting a blood sample in a lysing agent, such as deionised distilled water, preferably at a concentration of 1/1 (i.e. 1 part blood to 1 part lysing agent or distilled deionised water). Alternatively the sample can be frozen to lyse the cells. If the blood sample is a dried blood spot, the blood spot capture material on which the sample is dried can be placed in a lysing agent e.g. distilled deionised water to
• the blood spot can be reconstituted in a suitable buffer prior to lysis.
• the blood sample is diluted preferably after lysis.
• the blood sample may be diluted 1/10 (i.e. one part sample in 10 parts diluent), 1/500, 1/1000, 1/200, 1/2500, 1/8000 or more.
• the sample is diluted 1/2000 i.e. one part blood sample in 2000 parts diluent.
• the diluent is 0.1% trifluoroacetic acid in distilled deionised water, more preferably distilled deionized water.
• the blood sample is not processed between lysis and dilution.
• the blood sample is only lysed and diluted.
• processing includes concentrating the proteins of interest e.g. Hb, a-globin and/or ⁇ -globin; isolating Hb, a-globin and/or ⁇ -globin by for example HPLC or treatment with a chemical agent to disrupt or break intramolecular bonds.
• the sample is preferably not treated with a reducing agent. More preferably the sample is not treated with dithiothrietol (DTT).
• DTT dithiothrietol
• the proportion of glycated ⁇ -globin and/or ⁇ -globin can be calculated i.e. percentage of a-globin and/or ⁇ -globin which is glycated. The percentage is calculated as Glycated globin
• a level of >4% glycated a-globin and >6% ⁇ -globin is indicative of diabetes.
• a level of 3 - 4% glycated ⁇ -globin and 4-6% glycated ⁇ -globin is indicative of prediabetes.
• Y axis in these spectra is an indicator of "relative strength" of mass peak within the spectra, but not between mass peaks in one sample versus another sample.
• normalisation needs to render Y axis value comparable between sample spectra.
• the spectra obtained from the direct mass spectral analysis is preferably normalised.
• the spectra is subjected to data processing which results in a normalised statistically determined index of relative proportion of mass spectra. This converts the qualitative mass spectra into a quantitative value. Normalization is the process of producing a data structure to reduce repetition and inconsistencies of data.
• Typical normalisation methods include percentage of total area at a given point, Square difference and ratio of differences. The percentage difference is calculated as
• Y ref is the minimum Y value of the spectra
• Yl is Y value for each point.
• the ratio difference is calculated as
• Ratio Difference ( Ratio 1-Ratio 2) .
• the data from the mass spectra is manipulated in order to provide a quantitative measure of the qualitative change shown on the spectra.
• the spectral model is created by a method of data processing which results in a normalised statistically determined index of relative proportion of mass spectra within a set range. This renders all spectra comparable such that the median and centile variability at any given mass value can be modelled.
• the range is between about 7,000-16,500 m/z, more preferably 7,500-16,200m/z, most preferably 7,500-8,200 m/z.
• the single charged and/or double charged molecules of globin can be measured.
• the spectra at the mass/charge range of 15000 m/z to 16200 m/z is examined.
• the spectra at the mass/charge range of 6000 to 8100m/z, more preferably 7550 to 8100 m/z or 7550 to 8200m/z is examined.
• a- globin is preferably measured at 7564 m/z ⁇ 5m/z
• Glycated a globin is preferably measured at 7645 m/z ⁇ 5m/z
• ⁇ -globin is preferably measured at 7934 m/z ⁇ 5m/z
• Glycated ⁇ -globin is preferably measured at 8017 m/z ⁇ 5m/z
• a normalised statistically determined index of relative proportion of mass spectra within a given range can be calculated from using the total area under the curve of mass spectra. This can then be used to calculate the relative intensity.
• the area under the curve of mass spectra is calculated by dividing the mass spectra into a plurality of bins of a given number of m/z.
• Bin has its usual statistical meaning , for example, of being one of a series of ranges of numerical value into which data are sorted in statistical analysis.
• the bins can be 100m/z, 50m/z, 25m/z, lOm/z or 5m/z in size. The smaller the size of the bin used, the more refined the method. Preferably the bin size is 5m/z.
• the relative intensity (Y Axis value) can be calculated by the "square of difference” method and therefore a comparable Y value given for every bin.
• the minimum Y value of the spectra (Y ref) was subtracted from the Y value at every bin and the difference was squared.
• the formula used to calculate square of difference (yl-yref) 2 and the calculated square of difference was then named as "relative intensity”.
• the relative intensity at each mass bin in a sample can be captured using commercially available statistical tests such as MATLAB ® , Stats DirectTM and Origin 8TM.
• the relative intensity for the mass bins for (i) a- globin and glycated a- globin and/or (ii) ⁇ - globin and glycated ⁇ globin can be used to calculate the proportion of glycated globin present.
• the spectra at the mass/charge range of 15000 m/z to 16200 m/z is examined.
• the spectra at the mass/charge range of 6000 to 8100m/z, more preferably 7550 to 8200 m/z is examined.
• a- globin is preferably measured at 7564 m/z ⁇ 10m/z
• Glycated a globin is preferably measured at 7645 m/z ⁇ 10m/z
• ⁇ -globin is preferably measured at 7934 m/z ⁇ 10m/z
• Glycated ⁇ -globin is preferably measured at 8038 m/z ⁇ 10m/z
• the analysis of the mass spectra can be easily calculated using a suitable computer software program.
• the mass spectral analysis carried out is matrix-assisted laser desorption/ionization time- of-flight mass spectrometry (MALDI-ToF MS).
• MALDI-ToF MS matrix-assisted laser desorption/ionization time- of-flight mass spectrometry
• a method of detecting pre-diabetes or diabetes comprising a) obtaining a blood sample from a subject; b) subjecting the sample to direct mass spectral analysis; c) Calculating the proportion of glycated globin present; wherein a percentage glycated a globin >4% and >6% glycated ⁇ -globin is indicative of diabetes, and a percentage glycated globin between 3-4% for a -globin and 3-6% for ⁇ -globin is indicative of pre-diabetes.
• the percentage of glycated globin is the percentage glycated a -globin, in particular in subjects with a hemoglobinopathy.
• Figure 1 shows a spectra of normal blood in a 12 year old male
• Figure 2 shows a spectra of normal blood in an obese 52 year old male
• Figure 3 shows a spectra of blood in a patient with sickle cell disease HbSC
• Figure 4 shows an overlay of the 12 year old boy and 52 year old male blood spectra.
• Figure 5 A table of calculated relative amounts of glycated a-globin and ⁇ -globin and other globin molecules in 9 adults and 7 patients with various hemoglobinopathies
• the optimal dilution for whole blood or dried blood spot is between 1/1000 and 1/2000 in either ddH 2 0 or 0.1% TFA in ddH 2 0 after an initial lysis of sample with ddH 2 0 (1:1 v/v).
• This dilutional step effectively purifies the Hb from other components of blood for mass spectral analysis as Hb is the most abundant protein.
• the dilution in ddH 2 0 (of 0.1% TFA/ddH 2 0) dissociates the constituent globin proteins for resolved analysis by MALDI-ToF Mass spectrometry.
• the optimal matrices are sinnapinic acid (SA), ferulic acid (FA) and alpha 4- cyano hydroxycinnamic acid (CHCA).
• SA sinnapinic acid
• FA ferulic acid
• CHCA alpha 4- cyano hydroxycinnamic acid
• Sinapinic acid being the preferred matrix mixed or as pre -coating layer to a mixed drop of 1/1000 to 1/8000 diluted sample (optimal 1/2000).
• the ions were accelerated by a 20 kV electrical field down a 1.2 m linear tube and detected by a micro-channel plate detector at a sampling rate of 500 M Hz.
• Spectra were generated by summing 20-30 laser shots. A positive linear mode with delayed extraction was used in order to acquire the spectra.
• a mass spectral region of between 6,000 and 17,000m/z was collected and analysed and in particular the range of 7500 to 8200 m/z examined for doubly charged globin proteins.
• Figure 1 spectra of blood globins from a boy of 12 years .
• Figure 2 spectra of blood globins from a 52 year old man.
• a normal but obese adult blood sample reveals peaks for a- globin and ⁇ -globin along with their associated SA adducts.
• elevated ⁇ -globin is noted along with other a and ⁇ -globin adducts, whilst other globins ( Gy, Ay and ⁇ ) are barely detected (see figure 2 and table 1).
• the blood sample revealed glycated a-globin and ⁇ -globin peaks representing 3% and 5% of the parent globins.
• Figure 3 spectra of blood globins from a patient with Hb SC - Sickle cell diseases.
• Blood sample from a patient with sickle cell disease (HbSC) Figure 3 revealed normal and glycated a- globin peaks and a peak for s at 7920 m/z clearly resolved from ⁇ -globin at 7934 m/z and ⁇ ⁇ approx. 7933 m/z. Baseline elevation of ⁇ and Gy globins at 7965 and 7996 m/z was evident as was a new peak at 8023 m/z.
• the blood sample revealed normal and glycated ⁇ -globin peaks and the % comparison of intensity was 1.8% whilst the glycated ⁇ -globin was 6.3% of the parent ⁇ -globin.
• Figure 4 Comparison of blood globins of a 52 year old male and a 12 year old boy.
• Figure 5 Tabulated comparison of 9 adult spectra peak intensities with that from 7 assorted hemoglobinopathy patients.
• Glycated a-chain was detected in all samples and was clearly resolved in phenotypically normal samples and those with hemoglobinopathies, including sickle cell disease. Glycated ⁇ -globin was clearly distinguishable in all normal samples, but compromised by fetal globin expression which was generally elevated in all hemoglobinopathies (Figure 5). Expressed as a percentage of the a-globin intensity, the glycated ortholog represented between 0.5 and 3% (mean 1.78%, SD 0.79%) for phenotypic normal adults; and between 1 and 2.7% (mean 2.1, SD 0.57%) for those with hemoglobinopathies, including carriers.
• the glycated ortholog represented between 2 and 5.2% (mean 3.15%, SD 1.07%) for phenotypic normal adults; and between 0 and 9.1% (mean 5.1%, SD 2.78%) for those with hemoglobinopathies including carriers (see figure 5).
• HbAlc was first identified as a chromatographic fraction of Hemoglobin in 1971 and characterized as a measure of the beta-N-l-deoxy fructosyl component of hemoglobin. Normal levels of glucose produce a normal amount of glycated hemoglobin. As the average amount of plasma glucose increases, the fraction of glycated hemoglobin increases in a predictable way. This serves as a marker for average blood glucose levels over the previous 3 months prior to the measurement as this is the half-life of red blood ceils.
• HbAlc in type 1 diabetic patients has been adopted as a measure to improve outcomes.
• HPLC high-density polychromatic chromatin
• immunoassay and capillary electrophoresis are in clinical use.
• Largely regarded as a measure of ⁇ -giobin glycation its measurement is compromised by fetal ⁇ -!ike globin expression and with ⁇ -giobin gene mutations such as in sickle cell disease and beta-thaiassemia, and carriers of such mutation.
• elevated glycation has recently been shown to be associated with such hemoglobinopathies and may reflect an increased chemical susceptibility to glycation in such affected blood cells.
• the present method clearly resolves the glycated forms of a- and ⁇ -globin from each other and their respective non-glycated parents. This gives a finer discrimination of the glycation of hemoglobin and is not compromised by the presence of a mutation or aberrant globin gene expression that adversely affects other methods to measure Hb glycation.
• MALDI-Tof MS spectral analysis of drop or dried spot whole blood, following 1/2000 dilution in ddH20 reveals resolved globin proteins and clear resolution of glycated orthologo of a and ⁇ globins. Comparison of signal intensity of the glycated ⁇ -globin peak to the parent ⁇ -globin peak represents a rapid and economic screening and monitoring testing method for diabetes and pre-diabetes.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Physics & Mathematics (AREA)
• Hematology (AREA)
• Immunology (AREA)
• Biomedical Technology (AREA)
• Urology & Nephrology (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Computational Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Pathology (AREA)
• Food Science & Technology (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• Cell Biology (AREA)
• General Physics & Mathematics (AREA)
• Medicinal Chemistry (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Spectroscopy & Molecular Physics (AREA)
• Biophysics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Optics & Photonics (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=51752373

Family Applications (1)

Country Status (6)

Cited By (1)

Families Citing this family (6)

Family Cites Families (13)

• 2014
  • 2014-08-29 GB GBGB1415369.6A patent/GB201415369D0/en not_active Ceased
• 2015
  • 2015-08-27 WO PCT/GB2015/052487 patent/WO2016030687A1/en not_active Ceased
  • 2015-08-27 JP JP2017511664A patent/JP2017525972A/ja active Pending
  • 2015-08-27 EP EP15760506.4A patent/EP3186641B1/en active Active
  • 2015-08-27 US US15/506,731 patent/US10161941B2/en active Active
  • 2015-08-27 CN CN201580046748.8A patent/CN107209189B/zh active Active

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events